PriceTargets.com logo

Schrodinger - SDGR Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $26.00
  • Forecasted Upside: 41.15%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$18.42 As of 12/4/2025 05:00 PM ET
▲ +0.68 (3.83%)

This chart shows the closing price for SDGR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Schrodinger Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SDGR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SDGR

Analyst Price Target is $26.00
▲ +41.15% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Schrodinger in the last 3 months. The average price target is $26.00, with a high forecast of $45.00 and a low forecast of $19.00. The average price target represents a 41.15% upside from the last price of $18.42.

This chart shows the closing price for SDGR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 7 investment analysts is to hold stock in Schrodinger. This rating has held steady since September 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025KeyCorpLower TargetOverweight ➝ Overweight$30.00 ➝ $28.00
9/29/2025The Goldman Sachs GroupInitiated CoverageNeutral$19.00
9/29/2025The Goldman Sachs GroupUpgradeHold
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/18/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$28.00 ➝ $19.00
8/15/2025CitigroupDowngradeBuy ➝ Neutral$35.00 ➝ $20.00
8/14/2025BarclaysInitiated CoverageOverweight$25.00
8/14/2025BarclaysInitiated CoverageOverweight$25.00
7/14/2025KeyCorpLower TargetOverweight ➝ Overweight$32.00 ➝ $30.00
7/3/2025Morgan StanleyInitiated CoverageEqual Weight$28.00
4/16/2025KeyCorpBoost TargetOverweight ➝ Overweight$30.00 ➝ $32.00
2/27/2025Piper SandlerLower TargetOverweight ➝ Overweight$50.00 ➝ $45.00
1/24/2025KeyCorpBoost TargetOverweight ➝ Overweight$25.00 ➝ $27.00
11/13/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$25.00 ➝ $28.00
10/17/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$30.00 ➝ $25.00
8/21/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$43.00 ➝ $30.00
7/11/2024KeyCorpLower TargetOverweight ➝ Overweight$30.00 ➝ $25.00
7/2/2024Leerink PartnrsUpgradeStrong-Buy
7/2/2024Leerink PartnersInitiated CoverageOutperform$29.00
5/2/2024CitigroupLower TargetBuy ➝ Buy$39.00 ➝ $37.00
5/2/2024Craig HallumLower TargetBuy ➝ Buy$35.00 ➝ $30.00
3/1/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$29.00 ➝ $26.00
2/29/2024KeyCorpLower TargetOverweight ➝ Overweight$38.00 ➝ $33.00
2/29/2024CitigroupLower TargetBuy ➝ Buy$47.00 ➝ $39.00
2/29/2024Bank of AmericaLower TargetNeutral ➝ Neutral$38.00 ➝ $32.00
2/29/2024Piper SandlerLower TargetOverweight ➝ Overweight$60.00 ➝ $50.00
1/26/2024TD CowenInitiated CoverageOutperform$42.00
1/19/2024Craig HallumLower TargetBuy ➝ Buy$40.00 ➝ $35.00
12/5/2023KeyCorpInitiated CoverageOverweight$38.00
11/13/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$52.00 ➝ $51.00
8/4/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$52.00
8/3/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$78.00 ➝ $67.00
6/29/2023Morgan StanleyBoost Target$38.00 ➝ $52.00
6/15/2023Jefferies Financial GroupBoost Target$40.00 ➝ $60.00
5/8/2023CitigroupLower Target$52.00 ➝ $50.00
5/5/2023Piper SandlerInitiated CoverageOverweight$60.00
3/10/2023Morgan StanleyBoost TargetEqual Weight$38.00 ➝ $39.00
3/1/2023BMO Capital MarketsLower TargetOutperform$83.00 ➝ $78.00
1/31/2023CitigroupBoost TargetBuy$48.00 ➝ $51.00
1/19/2023Piper SandlerBoost TargetOverweight$86.00 ➝ $87.00
12/19/2022The Goldman Sachs GroupInitiated CoverageNeutral$23.00
11/4/2022BMO Capital MarketsLower TargetOutperform$88.00 ➝ $83.00
11/4/2022Morgan StanleyLower TargetEqual Weight$39.00 ➝ $38.00
11/4/2022CitigroupLower Target$55.00 ➝ $48.00
9/9/2022Morgan StanleyBoost TargetEqual Weight$33.00 ➝ $39.00
8/24/2022Morgan StanleyLower TargetEqual Weight$34.00 ➝ $33.00
7/26/2022Piper SandlerBoost TargetOverweight$84.00 ➝ $86.00
2/28/2022CitigroupInitiated CoverageBuy$55.00
2/25/2022Piper SandlerLower Target$87.00 ➝ $84.00
11/19/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$82.00 ➝ $49.00
11/18/2021Piper SandlerInitiated CoverageOverweight$87.00
11/11/2021Craig HallumLower TargetBuy$85.00 ➝ $80.00
11/11/2021Bank of AmericaDowngradeBuy ➝ Neutral$80.00 ➝ $52.00
10/13/2021Berenberg BankInitiated CoverageBuy$91.00
9/1/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$82.00
5/25/2021Craig HallumInitiated CoverageBuy$85.00
5/12/2021Morgan StanleyLower TargetEqual Weight$89.00 ➝ $83.00
3/24/2021BMO Capital MarketsLower TargetOutperform$110.00 ➝ $104.00
1/25/2021BMO Capital MarketsBoost TargetOutperform$97.00 ➝ $117.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.79 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 21 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/8/2025
  • 29 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2025
  • 6 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
7/7/2025
  • 9 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 17 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
9/5/2025
  • 9 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 10 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 13 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 13 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Schrodinger logo
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Read More

Today's Range

Now: $18.42
Low: $17.50
High: $18.42

50 Day Range

MA: $19.32
Low: $16.33
High: $22.52

52 Week Range

Now: $18.42
Low: $15.99
High: $28.47

Volume

720,261 shs

Average Volume

975,070 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Schrodinger?

The following Wall Street analysts have issued research reports on Schrodinger in the last year: Barclays PLC, Citigroup Inc., KeyCorp, Morgan Stanley, Piper Sandler, The Goldman Sachs Group, Inc., Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for SDGR.

What is the current price target for Schrodinger?

0 Wall Street analysts have set twelve-month price targets for Schrodinger in the last year. Their average twelve-month price target is $26.00, suggesting a possible upside of 41.2%. Piper Sandler has the highest price target set, predicting SDGR will reach $45.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $19.00 for Schrodinger in the next year.
View the latest price targets for SDGR.

What is the current consensus analyst rating for Schrodinger?

Schrodinger currently has 1 sell rating, 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SDGR, but not buy more shares or sell existing shares.
View the latest ratings for SDGR.

What other companies compete with Schrodinger?

Other companies that are similar to Schrodinger include Legend Biotech, CRISPR Therapeutics, TG Therapeutics, Apogee Therapeutics and Praxis Precision Medicines. Learn More about companies similar to Schrodinger.

How do I contact Schrodinger's investor relations team?

Schrodinger's physical mailing address is 120 WEST 45TH STREET 17TH FLOOR, NEW YORK NY, 10036. The company's listed phone number is 212-295-5800 and its investor relations email address is [email protected]. The official website for Schrodinger is www.schrodinger.com. Learn More about contacing Schrodinger investor relations.